

पेटेंट कार्यालय
शासकीय जर्नल

**OFFICIAL JOURNAL
OF
THE PATENT OFFICE**

निर्गमन सं. 22/2026
ISSUE NO. 22/2026

शुक्रवार
FRIDAY

दिनांक: 29/05/2026
DATE: 29/05/2026

पेटेंट कार्यालय का एक प्रकाशन
PUBLICATION OF THE PATENT OFFICE

(54) Title of the invention : PHYTOCHEMICAL SCREENING AND ANTIUROLITHIATIC ACTIVITY OF TAGETES ERECTA IN EXPERIMENTAL MODEL

(51) International classification	:G01N 33/15, A61K 127/00, G01N 30/02, G01N 33/50, A61K 36/28	(71)Name of Applicant : 1)Mr. Himank Varshney Address of Applicant :Assistant Professor, Sahu Onkar Saran School of Pharmacy, Faculty of Pharmacy, IFTM University, Delhi Road (NH-24), Moradabad, Moradabad District, Uttar Pradesh – 244102, India Uttar Pradesh India 2)Mr. Ajeet Singh 3)Mr. Sukh Pal Kashyap 4)Mr. Ammu Pratap Singh 5)Mr. Anil Kumar 6)Ms. Ekta Upadhyay 7)Mr. Mukul Kumar
(31) Priority Document No	:NA	(72)Name of Inventor :
(32) Priority Date	:NA	1)Mr. Himank Varshney
(33) Name of priority country	:NA	2)Mr. Ajeet Singh
(86) International Application No	:	3)Mr. Sukh Pal Kashyap
Filing Date	:01/01/1900	4)Mr. Ammu Pratap Singh
(87) International Publication No	: NA	5)Mr. Anil Kumar
(61) Patent of Addition to Application Number	:NA	6)Ms. Ekta Upadhyay
Filing Date	:NA	7)Mr. Mukul Kumar
(62) Divisional to Application Number	:NA	
Filing Date	:NA	

(57) Abstract :

The present invention relates to phytochemical screening and antiurolithiatic activity of Tagetes erecta Linn. leaves evaluated through in vitro and in vivo experimental models. Chloroform and aqueous leaf extracts prepared by Soxhlet extraction and cold maceration respectively were screened for secondary metabolites including flavonoids, saponins, and phenolic compounds. Both extracts demonstrated significant antioxidant activity with IC₅₀ values of 64.17 and 72.6 micrograms per millilitre in DPPH assay respectively. In vitro calcium oxalate crystallization studies revealed significant reduction in crystal size by aqueous extract to 7.9 micrometres and chloroform extract to 8.2 micrometres. In vivo studies using 0.75 percent ethylene glycol-induced urolithiasis in Wistar rats at one hundred milligrams per kilogram dose demonstrated significant reduction in urinary calcium, oxalate, and phosphate, with normalization of magnesium levels. Histopathological analysis confirmed reduced crystal deposition and restoration of renal architecture. The invention provides a scientifically validated herbal therapeutic for kidney stone prevention and management.

No. of Pages : 16 No. of Claims : 10